Faculty Collaboration Database

Absence of immunohistochemical metallothionein staining in bladder tumor specimens predicts response to neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy. J Urol 1994 Dec;152(6 Pt 2):2272-5

Date

12/01/1994

Pubmed ID

7966723

DOI

10.1016/s0022-5347(17)31656-7

Scopus ID

2-s2.0-0028053552 (requires institutional sign-in at Scopus site)   36 Citations

Abstract

Pre-chemotherapy bladder tumor tissue was retrospectively analyzed in 21 patients treated with neoadjuvant cisplatin, methrotrexate and vinblastine. Immunohistochemical staining for 2 proposed mediators of drug resistance, p-glycoprotein and metallothionein, was performed and compared to chemotherapeutic response and survival. There was no significant relationship between staining for p-glycoprotein and the response to chemotherapy or survival. Patients with no detectable staining for metallothionein were statistically more likely to sustain a complete pathological response (p = 0.029) after chemotherapy than those with any detectable staining. No relationship between metallothionein immunostaining and survival was apparent. This study offers further evidence linking metallothionein in tumor resistance to cisplatin containing chemotherapy regimens.

Author List

Bahnson RR, Becich M, Ernstoff MS, Sandlow J, Cohen MB, Williams RD

Author

Jay I. Sandlow MD Chair, Professor in the Urologic Surgery department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Transitional Cell
Chemotherapy, Adjuvant
Cisplatin
Cystectomy
Humans
Lymph Node Excision
Metallothionein
Methotrexate
Retrospective Studies
Survival Analysis
Urinary Bladder
Urinary Bladder Neoplasms
Vinblastine